Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada

Vaccine

Volumn 27, Issue 50, 2009, Pages 7105-7109

  Poirier, Béatrice ^a   De Wals, Philippe ^b   Petit, Geneviève ^a   Erickson, Lonny J ^c   Pépin, Jacques ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NONE

Author keywords

Cost effectiveness; Economic analysis; Pneumococcal conjugate vaccine; Program evaluation

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; QUEBEC; VACCINES, CONJUGATE;

EID: 70350776495     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.057     Document Type: Article

References (31)

1. National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. CCDR 28-ACS-2 (2002) 1-32
2. Boulianne N., De Wals P., Deceuninck G., Douville-Fradet M., Fortin E., Jetté L., et al. Impact du programme d'immunisation par le vaccin pneumococcique conjugué heptavalent (VPC-7), au Québec, Canada (2007), Institut national de santé publique du Québec, Quebec City. http://www.inspq.qc.ca/publications/notice.asp Available at: http://www.inspq.qc.ca/publications/notice.asp?E=p&NumPublication=68 1
3. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25 (2006) 312-319
4. Whitney C.G., Pilishvili T., Farley M.M., Shaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 (2006) 1495-1502
5. Comité sur l'immunisation du Québec. Évaluation de la pertinence d'un programme d'immunisation contre les infections pneumococciques chez l'enfant comportant un nombre réduit de doses de vaccin conjugué (2005), Institut national de santé publique du Québec. http://www.inspq.qc.ca/publications/default.asp Available at: http://www.inspq.qc.ca/publications/default.asp?Submit=Oui&E=p&c l=1&Theme=35
6. Institut de la Statistique du Québec. Population par année d'âge et par sexe, Québec, 1er juillet 2006; 2007. Available at: http://www.stat.gouv.qc.ca/donstat/societe/demographie/struc_poplt/201_0 6.htm.
7. De Wals P., Petit G., Erickson L.J., Guay M., Tam T., Law B., et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 21 (2003) 3757-3764
8. De Wals P., Jetté L., Sévin E., Ouakki M., Boulianne N., Douville-Fradet M., et al. Changes in the epidemiology of invasive pneumococcal disease (IPD) following implementation of a 7-valent pneumococcal conjugate vaccine (PCV7) program in Quebec, Canada. Proceedings of the 48th annual ICAAC and the IDSA 46th annual meeting. October 25-October 28, Washington, DC (2008)
9. Petit G., De Wals P., Law B., Tam T., Erickson L.J., Guay M., et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 14 (2003) 215-220
10. Shariatzadeh M.R., Huang J.Q., Tyrrell G.J., Johnson M.M., and Marrie T.J. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore) 84 (2005) 147-161
11. Morrow A., De Wals P., Petit G., Guay M., and Erickson L.J. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 18 (2007) 121-127
12. Nelson J.C., Jackson M., Yu O., Whitney C.G., Bounds L., Bittner R., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia children and adults. Vaccine 26 38 (2008) 4947-4954
13. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., and Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 27 (2008) 963-968
14. De Wals P, Carbon M, Sévin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J; in press.
15. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., Lafleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119 (2007) 707-715
16. Statistique Canada. Décès 2004. Le Quotidien; 2006. Available at: http://www.statcan.gc.ca/daily-quotidien/061220/dq061220b-fra.htm.
17. Statistics Canada. Labour force characteristics by age and sex (rates); 2007. Available at: http://www40.statcan.ca/101/cst01/labor20b.htm.
18. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22 (2004) 4203-4214
19. Dubé E., De Wals P., Gilca V., Boulianne N., Ouakki M., and Lavoie F. Consequences of acute otitis media in Canada. Social burden and impact on the quality of life. Poster P-62. 8th Canadian Immunization Conference. Can J Infect Dis Med Microbiol 19 (2008) 354
20. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G. Methods for the economic evaluation of health care programmes. third ed. (2005), Oxford University Press Inc., New York
21. Guay M., Blackburn M., Clément P., Tremblay A., St-Hilaire C., Clouâtre A.M., et al. Étude sur les coûts et l'efficacité du programme de vaccination des enfants de 0-2 ans au Québec (2006), Institut national de santé publique du Québec. http://www.inspq.qc.ca/publications/liste.asp Available at: http://www.inspq.qc.ca/publications/liste.asp?E=p&Theme=32
22. Beutels P, Van Damme P, Oosterhuis-Kajeva F. Effecten en kosten van de vaccinatie van Belgische kinderen met geconjugeerd pneumococcenvaccin. Health Technology Assessment (HTA). Brussels (Belgium): Federal Kenniscentrum voor de gezondheidszorg (KCE). KCE reports 33A (D/2006/10.273/21).
23. Beutels P., Thiry N., and Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25 (2007) 1355-1367
24. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146 (1992) 473-481
25. Lebel M.H., Kellner J.D., Ford-Jones E.L., Hvidsten K., Wang E.C.Y., Ciuryla V., et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 36 (2003) 259-268
26. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. For the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 (2007) 1346-1354
27. Grenier C., Pépin J., Nault V., and Valiquette L. Population incidence of community-acquired pneumonia requiring hospitalization in a region of Canada. Proceedings of the 48th annual ICAAC and the IDSA 46th annual meeting. October 25-October 28, Washington, DC (2008)
28. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., and Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine. Evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25 (2006) 494-501
29. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season. Can Commun Dis Rep 30 (2004) 1-3
30. Jansen A.G.S.C., Sanders E.A.M., Hoes A.W., Van Loon A.M., and Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. J Pediatr 153 (2008) 764-770
31. Boulianne N., Audet D., and Ouakki M. Enquête sur la couverture vaccinale des enfants québécois en 2006 (2007), Institut national de santé publique du Québec. http://www.inspq.qc.ca/publications/liste.asp Available at: http://www.inspq.qc.ca/publications/liste.asp?E=p&Theme=32